Vident Advisory, LLC Bei Gene, Ltd. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Vident Advisory, LLC holds 1,567 shares of BGNE stock, worth $310,657. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,567Holding current value
$310,657% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.5MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.1 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.39 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.03 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$989 Million0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$730 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.6B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...